Prescription Status and Clinical Outcomes of Methylxanthines and Leukotriene Receptor Antagonists in Mild-to-Moderate Chronic Obstructive Pulmonary Disease

Background: Methylxanthines and leukotriene receptor antagonists (LTRA) are not a first-line medical treatment for chronic obstructive pulmonary disease (COPD) but are frequently prescribed despite limited evidence. We aimed to elucidate the real prescribing status and clinical impacts of these agents in early COPD patients.

Methods: Patients with mild-to-moderate COPD (FEV$_1$ >50%) were selected from the Korean National Health and Nutrition Examination Survey data between 2007 and 2012. Besides analyzing the prescription status of methylxanthines and LTRA and the contributing factors to the prescription, we evaluated the clinical impacts of these drugs on the exacerbation, hospitalization, and medical costs.

Results: Of 2269 patients with mild-to-moderate COPD, 378 patients (16.7%) were under drug prescriptions. The LTRA users had more hospital utilization but did not have significant differences in acute exacerbations, hospitalizations, and medical costs, revealing the discrepancy between the guidelines and the real practice.

Conclusion: Methylxanthines and LTRA were used in a significant proportion of patients with mild-to-moderate COPD in real fields without favorable impacts on the exacerbations, hospitalizations, or medical costs. The use of more effective inhaled medications should be encouraged.

Keywords: pulmonary disease, chronic obstructive, methylxanthine, leukotriene antagonists, drug prescriptions

Summary

Methylxanthines and leukotriene receptor antagonists are not a first-line medical treatment for COPD; however, they were widely used in patients with mild-to-moderate COPD, without favorable impacts on the exacerbations, hospitalizations, or medical costs, revealing the discrepancy between the guidelines and the real practice.

Introduction

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide.$^{1,2}$ COPD causes persistent and progressive airflow limitation...
and leads to the decline of physical activity and quality of life in patients. The progression of COPD involves irreversible changes of the airway and lungs, and an improvement in clinical condition is more difficult in the advanced stages of the disease. There are many interests that early detection and treatment may have the beneficial effects in patients with COPD.

According to a study conducted in the United States, which was based on the data of the National Health and Nutrition Examination Survey, the overall age-adjusted prevalence of any obstructive lung disease was 13.5%, and 50% of the included cases had mild-to-moderate COPD. However, the prevalence of patients with mild-to-moderate COPD may be underestimated because these patients usually have fewer symptoms, and are less likely to use medical care.

Methylxanthines are non-selective phosphodiesterase inhibitors and play the roles of a bronchodilator and an enhancer of the inspiratory muscle function. Among them, theophylline may have favorable effects as a bronchodilator in treating functional impairments in patients with COPD, such as dyspnea, abnormal lung function, and decreased exercise capacity. Leukotriene receptor antagonists (LTRA) have anti-inflammatory and modest bronchodilatory effects on the airway. Despite the lack of definite evidence in COPD patients, some studies had demonstrated symptomatic improvements by LTRA.

Even though inhaled bronchodilators and corticosteroids are recommended as the main medical treatment options for COPD, oral agents including methylxanthines and LTRA have been prescribed frequently in real clinical fields. Furthermore, the patients with mild-to-moderate COPD tend to receive intermittent treatment according to symptoms and can be easily exposed to the oral agents to which they are relatively compliant than to the inhaled agents, which require educating the patient regarding the usage. However, there are limited studies about the real prescribing status of oral agents and their clinical impacts on mild-to-moderate COPD. We aimed to evaluate the prescribing status of oral methylxanthines and LTRA, to identify the contributing factors to the use of these medications, and to evaluate the clinical impacts of these medications on the course of mild-to-moderate COPD.

Methods

Study Design and Population

This retrospective cohort study was based on the Korean National Health and Nutrition Examination Survey (KNHANES) data from January 1, 2007, to December 31, 2012. The KNHANES is an annual survey conducted by the Ministry of Health and Welfare of Korea to investigate the health and nutrition levels of the Korean population and to establish and evaluate national health policies. KNHANES data included the data of COPD prevalence from 2007 onwards.

The inclusion criteria for the study were (1) patients with COPD based on the International Classification of Disease – 10th edition codes; and (2) mild-to-moderate severity of airflow limitation defined by the spirometry results (forced expiratory volume in the first second [FEV1] above 50% as the predicted value).

The National Health Insurance system, a compulsory universal health insurance system of Korea, has the medical claim data for all Koreans. We analyzed the data on the medical costs, source utilization, and medications used through the Health Insurance Review and Assessment (HIRA) service linked to this insurance system. The medications for the treatment of COPD included long-acting anti-muscarinic agents, inhaled corticosteroid/long-acting β2-agonists, methylxanthines, and LTRA. The criterion of patients under medical treatment was defined as the patients who received the maintenance treatment with the medication for more than one month. The Ethics Committee of Seoul Metropolitan Government – Seoul National University Boramae Medical Center approved the present study and waived the requirement for informed patient consent due to the retrospective nature of the study.

Outcomes

The primary outcome was the prescription pattern of oral methylxanthines and LTRA in patients with mild-to-moderate COPD. The secondary outcomes were the contributing factors for this pattern and the impact of these agents on the clinical outcomes and hospital utilizations. For this, we reviewed the data on history of acute exacerbation, outpatient clinic/emergency department visit, admission to hospital/intensive care unit, and overall medical costs for hospital utilizations via HIRA service. An acute exacerbation of COPD was defined as an event with aggravation of symptoms requiring the use of systemic corticosteroids, emergency department visit, or hospitalization. EuroQol-5-dimension (EQ-5D) questionnaire was used for estimating the quality of life in patients with COPD.

Statistical Analysis

The data are presented as means and standard deviations for continuous variables, and as numbers and percentages
for categorical variables. The proportion and differences between the groups were analyzed by Chi-square test or Fisher’s exact test. Multivariate logistic regression was applied to analyze the associations between the clinical factors and prescription of oral agents, the impact of oral agents on hospital utilization, and the dependent factors for the medical costs of hospital utilization. The odds ratio and adjusted odds ratio (aOR) are presented with 95% confidence intervals (CIs). A statistical significance was established with a P-value of 0.05 or less. All analyses were performed using SAS (version 9.2; SAS Institute, Cary, NC, USA) software package.

**Results**

**Baseline Characteristics of the Study Population**

In total, 2269 patients with mild-to-moderate COPD were included in this study, which was conducted between January 1, 2007, and December 31, 2012. The baseline characteristics of the study population are presented in Table 1. The mean age of the patients was 64.9 years, and 71.8% of the subjects were male. The proportion of current or ex-smokers was 69.3% with a mean smoking history of 21 pack-years. The most common comorbidity was hypertension (36.5%), and the prevalence of asthma was 8.4%. The mean FEV$_1$ was 2.3 L (78.8% as predicted value), and the proportion of mild severity of air flow limitation (FEV$_1$% predicted more than 80%) was 45.7%.

In 378 patients (16.7%) under treatment for COPD, the users of oral methylxanthines, LTRA, and inhaler were 255 (67.5%), 70 (18.5%), and 139 (36.8%) patients, respectively, and 279 (73.8%) patients were oral methylxanthines and/or LTRA users. Among the patients on COPD treatment, 106 (28.0%) patients received a combination therapy with inhalers and oral methylxanthines/LTRA; however, only 33 (8.7%) patients were treated with inhalers alone (Figure 1).

**Contributing Factors for Prescribing Oral Methylxanthines and LTRA**

Oral methylxanthines were significantly more prescribed in patients with asthma (aOR, 5.49; 95% CI, 1.61–18.7; P<0.006) and allergic disease (aOR, 2.38; 95% CI, 1.39–4.08; P=0.002), lower lung function, and poorer quality of life (Table 2). The patients with FEV$_1$ between 50% and 65% were treated with oral methylxanthines 2.82 times more than that in patients with FEV$_1$ of 80% or more (95% CI, 1.63–4.86; P<0.001). In this population, the mean value of EQ-5D index was 0.9, and the patients with EQ-5D index value of 0.9 or less were treated with oral methylxanthines 1.91 times more than that in patients with EQ-5D index value of 0.9 or more (95% CI, 1.24–2.93; P=0.003). The prescription of LTRA was associated with comorbidity of allergic disease (aOR, 1.93; 95% CI, 1.02–3.68; P=0.045), but not with abnormal lung functions and poor quality of life.

| Table 1 Baseline Characteristics of Study Population |
|-------------------------------------|-----------------|
| Age, years | 64.9 ± 10.0 |
| Sex, male | 1630 (71.8) |
| Body mass index, kg/m$^2$ | 23.6 ± 2.8 |
| Smoking history | |
| Never smoker | 697 (30.7) |
| Current or ex-smoker | 1572 (69.3) |
| Pack-years | 21.0 ± 23.3 |
| Previous pulmonary tuberculosis | 285 (12.6) |
| Comorbidities | |
| Hypertension | 828 (36.5) |
| Diabetes melitus | 323 (14.2) |
| Asthma | 191 (8.4) |
| Coronary heart disease | 88 (3.9) |
| Depression | 79 (3.5) |
| Stroke | 64 (2.8) |
| Other allergic diseases | 29 (1.3) |
| Baseline lung function test | |
| FEV$_1$, L | 2.3 ± 0.6 |
| FEV$_1$, % predicted | 78.8 ± 13.7 |
| FVC, L | 3.5 ± 0.9 |
| FVC, % predicted | 90.6 ± 13.6 |
| FEV$_1$/FVC ratio | 0.6 ± 0.1 |
| Severity of airflow limitation | |
| FEV$_1$, % predicted ≥80 | 1037 (45.7) |
| 65≤ FEV$_1$, % predicted <80 | 867 (38.2) |
| 50≤ FEV$_1$, % predicted <65 | 365 (16.1) |
| EQ-5D index values | 0.9 ± 0.2 |
| Use of inhalers | |
| LAMA | 139 (6.12) |
| ICS/LABA | 81 (3.6) |
| Use of oral methylxanthines/LTRA | |
| Methylxanthines | 279 (12.3) |
| LTRA | 255 (11.2) |
| LTRA | 70 (3.1) |

*Note:* Data are presented as n (%) or mean ± SD, unless otherwise stated.

*Abbreviations:* FEV$_1$, forced expiratory volume during the first second; FVC, forced vital capacity; EQ-5D, EuroQol-5 dimension; LAMA, long-acting anti-muscarinic agent; ICS/LABA, inhaled corticosteroid/long-acting β$_2$-agonist; LTRA, leukotriene receptor antagonist.
The use of oral methylxanthines and LTRA was significantly associated with the specialty of prescribing doctors, especially when the specialty was internal medicine. The type of institution showed a significant association with the prescriptions from private hospitals only in oral methylxanthine users. The combined treatment with inhalers was associated with the use of LTRA (aOR, 4.87; 95% CI, 2.53–9.40; P<0.001) and not with use of methylxanthines.

Clinical Outcomes and Medical Cost According to Use of Oral Methylxanthines and LTRA

During the follow-up period of 6 years, the users of oral methylxanthines and/or LTRA showed a significantly higher annual incidence rate of acute exacerbation and experienced more outpatient department/emergency room visits and hospital admissions than the non-users (Table 3). As a result, there was a significant difference in the total days of use for hospital utilizations; however, the annual medical costs were not significantly different between the users and non-users of oral methylxanthines and/or LTRA.

The use of oral methylxanthines and/or LTRA and inhalers were significant dependent factors of the annual occurrence of acute exacerbation in the univariate analysis, but only inhaler use was significant in the multivariate analysis (β ± SE, 0.136 ± 0.035; P<0.001) (Table 4). Further, the use of inhaler was the only significant dependent factor for annual medical cost of hospital utilization both in univariate and multivariate analyses (β ± SE, 238,300.0 ± 87,799.2; P<0.001) (Table 5).

Discussion

Through this study, we have demonstrated that oral methylxanthines and LTRA were widely used, and easily selected and prescribed in patients with mild-to-moderate COPD. The population of this study is expected to be approximately relevant to Global Initiative for Obstructive Lung Disease (GOLD) group A or B patients. Patients in GOLD group A are usually recommended to consider a symptom-based treatment with either a short-acting or a long-acting inhaled bronchodilator. Patients in GOLD group B are recommended to undergo treatment with a long-acting bronchodilator or consider a combination therapy with two bronchodilators depending on the initial symptoms and clinical progress. Recently, it was reported that inhaled tiotropium could ameliorate the annual FEV₁ decline even in patients with COPD of GOLD stage 1 or 2. However, our study had shown that in the actual field practice, the proportion of patients using inhalers fell short of that of patients treated with oral methylxanthines and LTRA, which take up far more than the recommended medicines in the selection of medication. This gap between the clinical guidance and the clinical practice has been identified in the previous Korean HIRA data analyses.

There are some evidences about the use of methylxanthines and LTRA in COPD patients. Theophylline, the most commonly used methylxanthine, has an anti-inflammatory effect against the neutrophilic airway inflammation dominant in COPD patients. Theophylline has a bronchodilator effect in respiratory muscles and a modest effect on the improvement of lung function, oxygenation, and symptoms via this mechanism. Further, some experimental and clinical studies had demonstrated that LTRA might have a role in reducing the neutrophilic and eosinophilic airway inflammation and airway hyperresponsiveness in obstructive lung disease, and improve symptoms and lung function, and reduce acute exacerbation of COPD patients with short-term and long-term use. The result of a recent meta-analysis supported the beneficial influences of LTRA on the improvement of symptoms in COPD patients, although the positive effects on lung function and inflammatory indexes were not confirmed. However, the evidence levels of studies supporting the use of methylxanthines and LTRA are low, and there are controversies between the existing data, whereas there is sufficient evidence to support the positive effects of inhaled bronchodilators on the clinical course of COPD patients. As a result, these oral agents are not strongly recommended to treat the patients with COPD.
However, the widespread use of oral methylxanthines and LTRA in the real medical fields despite the guidelines and evidence levels may be related to the accessibility of these drugs. Unlike the inhaled medications that require repeated education and training on how to use, oral medications do not require training for the medical staff and

Table 2 Contributing Factors of Prescription of Oral Methylxanthines and LTRA in Mild-to-Moderate COPD

| Dependent Variables | Methylxanthines | LTRA |
|---------------------|----------------|------|
|                     | aOR (95% CI)* | P value | aOR (95% CI)* | P value |
| Age, years          | 1.02 (1.00–1.05) | 0.075 | 1.01 (0.98–1.05) | 0.472 |
| Sex, male           | 1.64 (0.84–3.22) | 0.149 | 0.65 (0.27–1.56) | 0.340 |
| Body mass index, kg/m2 | 0.96 (0.89–1.04) | 0.301 | 1.10 (0.99–1.22) | 0.084 |
| Smoking history     |               |      |               |      |
| Never smoker        | 1 (ref)       |      | 1 (ref)       |      |
| Current or ex-smoker | 0.93 (0.48–1.78) | 0.821 | 1.84 (0.77–4.42) | 0.173 |
| Comorbidities       |               |      |               |      |
| Asthma              | 5.49 (1.61–18.7) | 0.006 | 1.40 (0.5–3.92) | 0.526 |
| Allergic disease    | 2.38 (1.39–4.08) | 0.002 | 1.93 (1.02–3.68) | 0.045 |
| Diabetes mellitus   | 0.72 (0.40–1.29) | 0.271 | 0.60 (0.25–1.44) | 0.256 |
| Cardiovascular disease | 0.91 (0.43–1.92) | 0.796 | 1.06 (0.36–3.10) | 0.921 |
| Severity of airflow limitation | | | |
| FEV1, % predicted ≥80 | 1 (ref) |      | 1 (ref) |      |
| 65≤ FEV1, % predicted <80 | 1.89 (1.17–3.05) | <0.001 | 1.17 (0.56–2.46) | 0.671 |
| 50≤ FEV1, % predicted <65 | 2.82 (1.63–4.86) | <0.001 | 1.65 (0.79–3.45) | 0.187 |
| Quality of life     |               |      |               |      |
| EQ-5D index values ≥0.9 | 1 (ref) | 0.003 | 1.34 (0.74–2.44) | 0.338 |
| EQ-5D index values <0.9 | 1.91 (1.24–2.93) |      |      |      |
| Specialty of prescribing doctors | | | |
| General practitioner vs specialist | 9.32 (1.82–47.83) | 0.008 | 0.43 (0.08–2.41) | 0.335 |
| Internal medicine vs non-internal medicine | 25.78 (12.54–53.02) | <0.001 | 46.49 (9.5–227.63) | <0.001 |
| Type of institution  |               |      |               |      |
| 2nd/3rd referral hospital | 1 (ref) |      | 1 (ref) |      |
| Private hospital    | 5.52 (3.04–10.04) | <0.001 | 0.92 (0.46–1.86) | 0.821 |
| Use of inhalers     | 0.94 (0.55–1.61) | 0.828 | 4.87 (2.53–9.40) | <0.001 |

Notes: Data are presented as n (%) or mean ± SD, unless otherwise stated. *Adjusted with age, sex, smoking history, and FEV1% predicted.

Table 3 Hospital Utilization According to Use of Oral Methylxanthines and/or LTRA in Mild-to-Moderate COPD

| Variables                        | Methylxanthines and/or LTRA User (n=279) | Methylxanthines and/or LTRA Non-User (n=1990) | P-value |
|----------------------------------|-----------------------------------------|-----------------------------------------------|---------|
| Frequency of acute exacerbation, times/yr | 0.4 ± 0.30 | 0.2 ± 0.15 | <0.001 |
| Total OPD visit                  | 12.9 ± 20.20 | 4.9 ± 8.82 | <0.001 |
| OPD visit, times/yr              | 2.2 ± 3.37 | 0.8 ± 1.47 | <0.001 |
| ER visit, times/yr               | 0.2 ± 0.14 | 0.2 ± 0.06 | 0.044 |
| Hospitalization, times/yr        | 0.3 ± 0.29 | 0.2 ± 0.15 | <0.001 |
| ICU, times/yr                    | 0.2 ± 0.07 | 0.2 ± 0.0 | 0.083 |
| Total used days                  | 21.2 ± 27.92 | 13.2 ± 19.16 | <0.001 |
| Cost/year, USD                   | 346,315.0 ± 671,806.1 | 370,182.0 ± 632,665.0 | 0.324 |

Abbreviations: OPD, outpatient department; ER, emergency room; ICU, intensive care unit; USD, United States dollar; yr, year.
patients and have no entry barrier for their use. In addition, COPD patients are usually elderly, with other oral medications for comorbid diseases and therefore, tend to be less resistant to oral medications. A low compliance with the inhaled drugs is also a cause for the frequent prescription of oral drugs. When older patients use inhalers, they often have difficulties in acquiring the correct technique of use. The low clinical effect due to an improper use of inhalers leads to poor inhaler compliance and may extend to the situation requiring an additional medication while maintaining the inhaler. Further, the results of lung function tests are needed to prescribe an inhaler device with insurance benefits in Korea. Since not all primary physicians have the resources for lung function tests, the prescription of oral medications is promoted instead of inhaled bronchodilators. This study revealed that oral methylxanthines were prescribed more in private hospitals comparing with second and third referral hospitals, and this phenomenon was supporting the previously mentioned hypothesis.

We observed that oral methylxanthines were prescribed more in patients with poorer lung function and quality of life, and even as a monotherapy in patients with mild-to-moderate COPD. On the other hand, LTRA was prescribed more in inhaler users and patients with allergic diseases. It may reflect the fact that LTRA has a less supportive background for use as a monotherapy in COPD patients, and a less beneficial effect on lung functions than by methylxanthines. It also suggests that LTRA was primarily used as an adjuvant therapy to control the airway hyperresponsiveness in COPD patients with allergic diseases or asthmatic component.

The annual frequencies of acute exacerbation, outpatient clinic/emergency room visit, and hospitalization were significantly higher in oral methylxanthines and/or LTRA users than non-users. However, users of methylxanthine had poorer lung function, compared with non-users. Patients with poorer lung function may be susceptible to more frequent exacerbations or hospitalization in medical practice. So, multivariate analysis showed that the use of methylxanthines and/or LTRA was not a dependent factor on acute exacerbation and medical cost after the correction of major risk factors including lung function. This does not mean that these drugs caused poor clinical outcomes but rather that these were widely used as alternative treatment modalities in situations where the inhaled medications

### Table 4: Dependent Factors for Annual Frequency of Acute Exacerbation in Patients with COPD

| Variable                         | Univariate |          | Multivariate |          |
|----------------------------------|------------|----------|--------------|----------|
|                                  | β ± SE     | p-value  | β ± SE       | p-value  |
| Age (years)                      | 0.004 ± 0.002 | 0.032   | 0.001 ± 0.002 | 0.633    |
| Male                             | 0.005 ± 0.029 | 0.864   | −0.004 ± 0.052 | 0.933    |
| FEV₁, %                          | −0.067 ± 0.024 | 0.005   | −0.057 ± 0.037 | 0.126    |
| Methylxanthines and/or LTRA use  | 0.122 ± 0.028 | <0.001  | 0.053 ± 0.031 | 0.088    |
| Current smoker                   | 0.022 ± 0.029 | 0.445   | 0.046 ± 0.041 | 0.261    |
| Use of inhalers                  | 0.175 ± 0.032 | <0.001  | 0.136 ± 0.035 | <0.001   |
| EQ-5D index                      | −0.033 ± 0.071 | 0.642   | 0.004 ± 0.069 | 0.959    |

**Abbreviations:** FEV₁, forced expiratory volume during the first second; LTRA, leukotriene receptor antagonist; EQ-5D, EuroQol-5 dimension.

### Table 5: Dependent Factors for Annual Cost of Hospital Utilization in Mild-to-Moderate COPD

| Variable                         | Univariate |          | Multivariate |          |
|----------------------------------|------------|----------|--------------|----------|
|                                  | β ± SE     | p-value  | β ± SE       | p-value  |
| Age (years)                      | 6427.3 ± 3126.2 | 0.040   | 5590.2 ± 365,835.8 | 0.125 |
| Male                             | −42,299.1 ± 59,713.3 | 0.479   | −89,850.4 ± 3637.6 | 0.393 |
| FEV₁, %                          | −93,114.3 ± 48,634.2 | 0.056   | −27,653.4 ± 105,063.8 | 0.706 |
| Methylxanthines and/or LTRA use  | −23,867.0 ± 55,958.6 | 0.670   | −107,942.0 ± 73,207.8 | 0.074 |
| Current smoker                   | −396.4 ± 59,318.9 | 0.995   | 97,904.0 ± 60,241.2 | 0.265 |
| Use of inhalers                  | 197,035.9 ± 63,622.4 | 0.002   | 238,300.0 ± 87,799.2 | <0.001 |
| EQ-5D index                      | −229,727.0 ±152,189.9 | 0.132   | −174,776.0 ± 68,257.7 | 0.264 |

**Abbreviations:** FEV₁, forced expiratory volume during the first second; LTRA, leukotriene receptor antagonist; EQ-5D, EuroQol-5 dimension.
could not be applied or as an adjuvant therapy with inhaled bronchodilators in an acute exacerbation and subsequently deconditioned status of COPD. On the other hand, considering the general medical reality of transferring patients that are not well controlled from primary to secondary and tertiary referral institutions, this study suggests that in real fields, oral methylxanthines and/or LTRA might be started in the private or second referral hospitals, and when the patients developed more symptoms with a decline in lung functions, they might be referred to the third referral or university-affiliated hospital and treated with inhalers. Although this could not explain all such cases, it could explain why inhaler users had significantly higher frequencies of acute exacerbations, and higher medical costs for hospital utilization than non-users. According to the results of this study, prescription patterns for oral medication differed depending on what level of institutions the doctors were working at or what the doctor’s specialty was. This suggests that doctor factor also contributes to drug selection. We found that not only the drug-related factors but also the medical behaviors of doctors and patients were important in determining the selection and use of drugs.

Only 16.7% of patients in our study population with mild-to-moderate COPD were under medical treatment. Even given that 54.3% of the population had patients with FEV1 between 50% and 80%, the proportion of patients treated was significantly lower. Low treatment rates relative to lung function as well as low awareness of COPD may be a problem in the management of COPD patients. According to the KNHANES result in 2008, only 2.4% and 2.1% of COPD patients confirmed by survey were diagnosed with COPD and treated prior to this survey, respectively.31 This reflects the actual clinical practice where the proportion of COPD patients was undervalued, and the physicians were reluctant to provide active treatment for patients with mild-to-moderate COPD, especially for those without marked symptoms. However, even early COPD patients may experience eventual disease progression, acute exacerbations, and more rapid decline of lung function.32-34 As previously mentioned, the results of a recent study showed that treatment with inhaled bronchodilators can improve lung function and reduce the decline of lung function in mild-to-moderate COPD.14 Further research is needed to assess whether an active screening and treatment will be beneficial to the long-term clinical course of patients with mild-to-moderate COPD.

Our study has several limitations. First, this study was based on a retrospective review and insurance claim data, and the prescriptions of medications were considered as the use of medications, but the drug compliance was not measured. Second, the evaluation of lung functions was based on the pre-bronchodilator data. In the KNHANES, post-bronchodilator pulmonary function tests were not performed due to safety concerns about bronchodilator use in general population. Third, the regional differences in the availability of these drugs and coverage spectrum by health insurances may limit the generalization of the results of this study to other countries.

In conclusion, oral methylxanthines and LTRA were widely used in patients with mild-to-moderate COPD, revealing the discrepancy between the guidelines and the real practice. The prescription of these agents was determined by comorbidities, lung function, quality of life of patients, and the prescribing doctor’s specialty and institution. The users of methylxanthines and LTRA had more hospital utilization but did not have significant differences in acute exacerbations and medical cost for hospital utilization, compared with non-users. The use of more effective inhaled medications should be encouraged.

**Abbreviations**

COPD, chronic obstructive pulmonary disease; LTRA, Leukotriene receptor antagonists; KNHANES, Korean National Health and Nutrition Examination Survey; FEV1, forced expiratory volume in the first second; HIRA, Health Insurance Review and Assessment; EQ-5D, EuroQol-5 dimension; aOR, adjusted odds ratio; CI, Confidence interval; GOLD, Global Initiative for Obstructive Lung Disease.

**Acknowledgments**

The abstract of this paper was presented at the American Thoracic Society Conference 2019 as a poster presentation on May 20, 2019 with interim findings. The poster’s abstract was published in “Poster Abstracts” in *American Journal of Respiratory and Critical Care Medicine* (Am J Resp Crit Care Med 2019;199:A3298; https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2019.199.1.MeetingAbstracts.A3298).

**Author Contributions**

All authors contributed toward data analysis, drafting and revising the paper, gave final approval of the version to be published and agree to be accountable for all aspects of the work. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

**Author Contributions**

All authors contributed toward data analysis, drafting and revising the paper, gave final approval of the version to be published and agree to be accountable for all aspects of the work. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Disclosure
C.K.R reports personal fees from MSD, AstraZeneca, GSK, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, and Bayer, outside of the submitted work. The authors report no other conflicts of interest in this work.

References
1. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet. 2007;370:741–750. doi:10.1016/S0140-6736(07)61377-4
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. doi:10.1016/S0140-6736(12)61728-0
3. Ford ES, Mannino DM, Wheaton AG, Giles WH, Presley-Cantrell L, Croft JB. Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010. Chest. 2013;143:1395–1406. doi:10.1378/chest.12-1135
4. Seo JY, Hwang YI, Mun SY, et al. Awareness of COPD in a high risk Korean population. Yonsei Med J. 2015;56:362–367. doi:10.3349/ymj.2015.56.2.362
5. ZuWallack RL, Maher DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001;119:1661–1670. doi:10.1378/chest.119.6.1661
6. Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;CD003902.
7. Lee JH, Kim HJ, Kim YH. The effectiveness of anti-leukotriene agents in patients with COPD: a systemic review and meta-analysis. Lung. 2015;193:477–486. doi:10.1007/s00408-015-9743-5
8. Lee J, Lee JH, Kim JA, Rhee CK. Trend of cost and utilization of COPD medication in Korea. Int J Chron Obstruct Pulmon Dis. 2017;12:27–33. doi:10.2147/COPD.S121687
9. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63:402–407. doi:10.1136/thx.2007.085456
10. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990;150:841–845.
11. Mellins RB, Evans D, Zimmerman B, Clark NM. Patient compliance. Are we wasting our time and don’t know it? Am Rev Respir Dis. 1992;146:1376–1377. doi:10.1164/ajrccm.146.6.1376
12. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195:557–582. doi:10.1164/rccm.201701-0218PP
13. Park YB, Rhee CK, Yoon HK, et al. Revised (2018) COPD clinical practice guideline of the Korean Academy of Tuberculosis and Respiratory Disease: a summary. Tuberc Respir Dis (Seoul). 2018;81:261. doi:10.4064/trd.2018.0029
14. Zhou Y, Zhong NS, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med. 2017;377:923–935. doi:10.1056/NEJMoa1700228
15. Culpitt SV, de Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165:1371–1376. doi:10.1164/ajrccm.165.6.1371
16. Kobayashi M, Nasuhara Y, Betsuyaku T, et al. Effect of low-dose theophylline on airway inflammation in COPD. Respirology. 2004;9:249–254. doi:10.1111/j.1440-1843.2004.00922.x
17. Shih YN, Chen YT, Chu H, et al. Association of pre-hospital theophylline use and mortality in chronic obstructive pulmonary disease patients with sepsis. Respir Med. 2017;125:33–38. doi:10.1016/j.rmed.2017.02.020
18. Jaeschke R, Guyatt GH, Singer J, Keller J, Newhouse MT. Mechanism of bronchodilator effect in chronic airflow limitation. CMAJ. 1991;144:35–39.
19. Vaz Fragoso CA, Miller MA. Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993;147:S40–S47. doi:10.1164/ajrccm.147.6 Pt. 2.540
20. Ikeda G, Miyahara N, Koga H, et al. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema. Am J Respir Cell Mol Biol. 2014;50:18–29. doi:10.1165/rcmb.2012-0418OC
21. Zuhlke IE, Kaniess F, Richter K, et al. Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD. Eur Respir J. 2003;22:926–930. doi:10.1183/09031936.03.0046203
22. Rubinstein I, Kumar B, Schriever C. Long-term montelukast therapy in moderate to severe COPD—a preliminary observation. Respir Med. 2004;98:134–138. doi:10.1016/j.rmed.2003.09.003
23. Celik P, Sakar A, Havluucu Y, Yuksel H, Turdogan P, Yorgancioglu A. Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med. 2005;99:444–450. doi:10.1016/j.rmed.2004.09.008
24. George J, Kong DC, Thoman R, Stewart K. Factors associated with medication nonadherence in patients with COPD. Chest. 2005;128:3198–3204. doi:10.1378/chest.128.5.3198
25. Mapel DW, Picchi MA, Hurley JS, et al. Utilization in COPD: patient characteristics and diagnostic evaluation. Chest. 2000;117:3456S–353S. doi:10.1378/chest.117.5_suppl.3456S
26. Dolce JJ, Crisp C, Manzella B, Richards JM, Hardin JM, Bailey WC. Medication adherence patterns in chronic obstructive pulmonary disease. Chest. 1991;99:837–841. doi:10.1378/chest.99.4.837
27. Chryssides E, Frewin DB, Frith PA, Dawes ER. Compliance with aerosol therapy in chronic obstructive lung disease. NZ Med J. 1981;94:375–377.
28. Incalzi RA, Pedone C, Onder G, Pahor M, PU C, Farmacovigilanza GId. Predicting length of stay of older patients with exacerbated chronic obstructive pulmonary disease. Aging (Milano). 2001;13:49–57.
29. George J, Ioannides-Demos LL, Santamaria NM, Kong DC, Stewart K. Use of complementary and alternative medicines by patients with chronic obstructive pulmonary disease. Med J Aust. 2004;181:248–251. doi:10.5694/j.mja1326-5377.2004.tb06262.x
30. Calverley PM, Tetzlaff K, Dusser D, et al. Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. Int J Chron Obstruct Pulmon Dis. 2017;12:3391–3405. doi:10.2147/COPD.S110461
31. Yoo KH, Kim YS, Sheen SS, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey 2008. Respiriology. 2011;16:659–665. doi:10.1111/j.1600-0404.2011.01114.x
32. Dransfield MT, Kuniyuki KM, Strand MJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:324–330. doi:10.1164/rccm.201605-1040OC
33. Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med. 2016;374:1811–1821. doi:10.1056/NEJMoa1505971
34. Rhee CK, Kim K, Yoon HK, et al. Natural course of early COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:663–668. doi:10.2147/COPD.S110461
